We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Olive Oil Compound Shows Potential as Treatment for Alzheimer's Disease

By LabMedica International staff writers
Posted on 12 Oct 2009
A component of extra virgin olive oil has been found to protect brain synapses from damage caused by the buildup of toxic soluble oligomers of amyloid-beta peptide (ADDLs) in patients with Alzheimer's disease (AD).

Most researchers now believe that soluble oligomers of amyloid-beta peptide, rather than insoluble fibrils, act as the primary neurotoxin in AD. More...
This has lead to a search for compounds capable of altering the assembly state of these oligomers and that may have potential for AD therapeutics.

One of these compounds is oleocanthal, which may be extracted from extra virgin olive oil. It is responsible for the slightly peppery "bite" of extra virgin olive oil, the cold-pressed result of the first pressing of the olives. This oil is only 1% acid and is considered the finest and fruitiest of the olive oils and is therefore the most expensive. Oleocanthal is a tyrosol ester, and its chemical structure is related to oleuropein that is also found in olive oil.

Oleocanthal has been found to have antiinflammatory and antioxidant properties. Similar to classical NSAIDs (nonsteroidal antiinflammatory drugs), it is a nonselective inhibitor of cyclooxygenase (COX). It has been suggested that long-term consumption of small quantities of oleocanthal from olive oil may be responsible in part for the low incidence of heart disease associated with a Mediterranean diet.

Investigators at Northwestern University (Evanston, IL, USA) studied the direct effect of oleocanthal on ADDL structure and on the binding of ADDLs to synapses.

They reported in the October 15, 2009, online edition of the journal Toxicology and Applied Pharmacology that treatment with oleocanthal increased the apparent size of ADDLs and rendered them more accessible to antibody binding. Treated ADDLs were found to be less able to interact with and bind to synapses of cultured hippocampal neurons. The hippocampus, a part of the brain intimately involved in learning and memory, is one of the first areas affected by AD.

"Binding of ADDLs to nerve cell synapses is thought to be a crucial first step in the initiation of Alzheimer's disease. Oleocanthal alters ADDL structure in a way that deters their binding to synapses," said senior author Dr. William L. Klein, professor of neurobiology and physiology at Northwestern University.

Related Links:

Northwestern University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.